Cargando…

Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail

The aim of this study was to characterize the effects of upadacitinib, a Janus kinase 1 inhibitor, on in vivo activity of different cytochrome P450 (CYP) enzymes using a cocktail approach. Healthy subjects (n = 20) received single oral doses of the modified Cooperstown 5+1 cocktail drugs (midazolam...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Mohamed‐Eslam F., Feng, Tian, Enejosa, Jeffrey V., Fisniku, Ogert, Othman, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972567/
https://www.ncbi.nlm.nih.gov/pubmed/31378969
http://dx.doi.org/10.1002/jcph.1496
_version_ 1783489859138093056
author Mohamed, Mohamed‐Eslam F.
Feng, Tian
Enejosa, Jeffrey V.
Fisniku, Ogert
Othman, Ahmed A.
author_facet Mohamed, Mohamed‐Eslam F.
Feng, Tian
Enejosa, Jeffrey V.
Fisniku, Ogert
Othman, Ahmed A.
author_sort Mohamed, Mohamed‐Eslam F.
collection PubMed
description The aim of this study was to characterize the effects of upadacitinib, a Janus kinase 1 inhibitor, on in vivo activity of different cytochrome P450 (CYP) enzymes using a cocktail approach. Healthy subjects (n = 20) received single oral doses of the modified Cooperstown 5+1 cocktail drugs (midazolam [CYP3A], caffeine [CYP1A2], warfarin + vitamin K [CYP2C9], omeprazole [CYP2C19], and dextromethorphan [CYP2D6]) without upadacitinib and on day 11 (midazolam) or 12 (all other probes) of a 15‐day regimen of upadacitinib 30 mg once daily (extended‐release formulation). Serial blood samples and 12‐hour urine samples were collected for assays of the probe substrates and select metabolites. The ratio (90%CI) of area under the plasma concentration‐time curve from time 0 to infinity (AUC(inf)) central values when the cocktail drugs were administered with upadacitinib relative to when administered alone were 0.74 (0.68‐0.80) for midazolam, 1.22 (1.15‐1.29) for caffeine, 1.11 (1.07‐1.15) for S‐warfarin, 1.07 (0.95‐1.22) for dextromethorphan, and 0.82 (0.72‐0.94) for omeprazole. The ratio (90%CI) was 1.09 (1.00‐1.19) for 5‐hydroxy‐omeprazole to omeprazole AUC(inf) ratio and 1.17 (0.97‐1.41) for dextromethorphan to dextrorphan 12‐hour molar urinary ratio. Upadacitinib 30 mg once daily (a dose that is twice the optimal dose in rheumatoid arthritis based on phase 3 results) has a limited effect on CYP3A activity (26% decrease in exposure of midazolam, a sensitive CYP3A substrate) and no relevant effects on CYP1A2, CYP2C9, CYP2C19, or CYP2D6 activity in vivo. No clinically relevant changes in plasma exposures are expected for drugs that are substrates for the evaluated CYP enzymes when coadministered with upadacitinib.
format Online
Article
Text
id pubmed-6972567
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69725672020-01-27 Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail Mohamed, Mohamed‐Eslam F. Feng, Tian Enejosa, Jeffrey V. Fisniku, Ogert Othman, Ahmed A. J Clin Pharmacol Drug Interactions The aim of this study was to characterize the effects of upadacitinib, a Janus kinase 1 inhibitor, on in vivo activity of different cytochrome P450 (CYP) enzymes using a cocktail approach. Healthy subjects (n = 20) received single oral doses of the modified Cooperstown 5+1 cocktail drugs (midazolam [CYP3A], caffeine [CYP1A2], warfarin + vitamin K [CYP2C9], omeprazole [CYP2C19], and dextromethorphan [CYP2D6]) without upadacitinib and on day 11 (midazolam) or 12 (all other probes) of a 15‐day regimen of upadacitinib 30 mg once daily (extended‐release formulation). Serial blood samples and 12‐hour urine samples were collected for assays of the probe substrates and select metabolites. The ratio (90%CI) of area under the plasma concentration‐time curve from time 0 to infinity (AUC(inf)) central values when the cocktail drugs were administered with upadacitinib relative to when administered alone were 0.74 (0.68‐0.80) for midazolam, 1.22 (1.15‐1.29) for caffeine, 1.11 (1.07‐1.15) for S‐warfarin, 1.07 (0.95‐1.22) for dextromethorphan, and 0.82 (0.72‐0.94) for omeprazole. The ratio (90%CI) was 1.09 (1.00‐1.19) for 5‐hydroxy‐omeprazole to omeprazole AUC(inf) ratio and 1.17 (0.97‐1.41) for dextromethorphan to dextrorphan 12‐hour molar urinary ratio. Upadacitinib 30 mg once daily (a dose that is twice the optimal dose in rheumatoid arthritis based on phase 3 results) has a limited effect on CYP3A activity (26% decrease in exposure of midazolam, a sensitive CYP3A substrate) and no relevant effects on CYP1A2, CYP2C9, CYP2C19, or CYP2D6 activity in vivo. No clinically relevant changes in plasma exposures are expected for drugs that are substrates for the evaluated CYP enzymes when coadministered with upadacitinib. John Wiley and Sons Inc. 2019-08-05 2020-01 /pmc/articles/PMC6972567/ /pubmed/31378969 http://dx.doi.org/10.1002/jcph.1496 Text en © 2019 AbbVie Inc. The Journal of Clinical Pharmacology published by Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Drug Interactions
Mohamed, Mohamed‐Eslam F.
Feng, Tian
Enejosa, Jeffrey V.
Fisniku, Ogert
Othman, Ahmed A.
Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail
title Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail
title_full Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail
title_fullStr Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail
title_full_unstemmed Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail
title_short Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail
title_sort effects of upadacitinib coadministration on the pharmacokinetics of sensitive cytochrome p450 probe substrates: a study with the modified cooperstown 5+1 cocktail
topic Drug Interactions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972567/
https://www.ncbi.nlm.nih.gov/pubmed/31378969
http://dx.doi.org/10.1002/jcph.1496
work_keys_str_mv AT mohamedmohamedeslamf effectsofupadacitinibcoadministrationonthepharmacokineticsofsensitivecytochromep450probesubstratesastudywiththemodifiedcooperstown51cocktail
AT fengtian effectsofupadacitinibcoadministrationonthepharmacokineticsofsensitivecytochromep450probesubstratesastudywiththemodifiedcooperstown51cocktail
AT enejosajeffreyv effectsofupadacitinibcoadministrationonthepharmacokineticsofsensitivecytochromep450probesubstratesastudywiththemodifiedcooperstown51cocktail
AT fisnikuogert effectsofupadacitinibcoadministrationonthepharmacokineticsofsensitivecytochromep450probesubstratesastudywiththemodifiedcooperstown51cocktail
AT othmanahmeda effectsofupadacitinibcoadministrationonthepharmacokineticsofsensitivecytochromep450probesubstratesastudywiththemodifiedcooperstown51cocktail